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Abstract
Small molecule chemotherapeutic agents such as Imatinib, Gefitinib, and 
Erlotinib have played a significant role in the treatment of cancer. Although 
the unprecedented progress has been achieved in cancer treatment with these 
targeted agents, there is a strong demand for the development of selective and 
highly efficacious cancer drugs. V-ATPases are emerging as important target for 
the identification of novel therapeutic agents for cancer. Our screening and drug 
discovery processes have identified the bisbenzimidazole derivative (RP-15) as 
a potent anticancer V-ATPase inhibitor. In the present study, bisbenzimidazoles 
(compound-25, RP-11 and RP-15) have been tested for proton-pump inhibition 
activity in human hepatoma cell line (Huh7.5). RP-15 displayed comparable 
proton-pump inhibition activity to the standard Bafilomycin A1. We examined 
the antiproliferative activity of these analogs in two highly invasive and metastatic 
inflammatory breast cancer (IBC) cell lines (SUM 149PT and SUM190PT) along 
with Huh7.5. The compound-25 (SUM190PT: IC50 = 0.43±0.11 μM) and its struc-
tural analog RP-11 (SUM190PT: IC50 = 0.49±0.09 μM) have shown significant 
inhibition toward IBC cell lines. Additionally, RP-11 and RP-15 have demon-
strated very good cytotoxicity toward the majority of cancer cell lines in the NCI 
60 cell line panel.
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1. Introduction
Since Paul Ehrlich’s introduction of the concept of chemotherapy, development 
of chemotherapeutic agents for cancer over the past several decades has seen mar-
velous records of accomplishments [1, 2]. Cancer is one of the major health prob-
lems globally and is second leading cause of death in the USA [3, 4]. Cancer is a very 
complex disease and our understanding towards it has been advanced tremendously 
over the last six decades since the first human cancer cell line HeLa identified in 
1952 [5]. Over the past few years, the search for new anticancer drugs has changed 
dramatically. Advances in the molecular nature of drug action, new technology and 
more recently market considerations have produced new approaches to cancer drug 
discovery [6]. Recent advances in molecular biology, high throughput screening 
Chemistry and Applications of Benzimidazole and its Derivatives
2
(HTS), computer-aided drug design (CADD), and combinatorial chemistry tech-
nologies have allowed a combination of both knowledge around the drug receptor 
and large library screening to be used for anticancer drug discovery today [7–10].
As the understanding of human biology and new technologies progressed, 
the discovery and development process moved from a random pattern to a more 
predictable one. The development of a molecularly targeted anticancer drug has 
gained importance in recent years [11]. One of the important small molecule 
targeted therapy, Imatinib (Gleevec®), a tyrosine kinase inhibitor, achieved 
incredible advancement in cancer treatment [12–14]. Imatinib’s success stimulated 
the scientists to develop variety of targeted anticancer agents including Gefitinib 
(Iressa™) and Erlotinib (Terceva®) for the treatment of different types of cancer 
patients (Figure 1). Targeted agents represented significant developments in cancer 
treatment and have increased the life expectancy of patients [15–18]. Despite the 
unprecedented progress achieved, the anticancer drug discovery research remains 
highly challenging and there is strong demand for the development of highly 
efficacious and safe anticancer drugs which can overcome cancer metastasis, and 
drug resistance.
Recent studies suggest that an acidic microenvironment in the tumor is 
responsible for cancer development, progression, and metastasis. Novel drugs that 
specifically target the mechanism by which V-ATPase lowers the pH of the tumor 
microenvironment are essential for cancer chemotherapy. Among the key regula-
tors of the tumor, acidic microenvironment V-ATPases plays an important role in 
the regulation of the pH gradient. V-ATPases play a vital role in the maintenance 
of the tumor acidic microenvironment and are overexpressed in many types of 
metastatic cancers including breast cancer. V-ATPases are functionally expressed in 
plasma membranes of tumor cells and they have specialized functions in metastasis 
[19]. Recent research has demonstrated that the preferential expression of V-ATPase 
at the cell surface is important for the acquisition of invasiveness and the metastasis 
of breast cancer cells [19]. Therefore, V-ATPase is a potential target to investigate for 
metastatic breast cancer therapy. Discovery and development of easily synthesized, 
Figure 1. 
Molecularly targeted clinically successful chemotherapeutic agents.
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cost-effective, and potent small molecule drugs targeting V-ATPase are needed 
to evaluate the therapeutic potential of V-ATPase inhibitors in metastatic breast 
cancer.
The V-ATPases are a family of ATP-driven proton pumps that couple ATP 
hydrolysis with translocation of protons across membranes. The V-ATPase proton 
pump is a macromolecular complex composed of at least 14 subunits organized 
into two functional domains, V1 is responsible for ATP hydrolysis and V0 provides 
the transmembrane proton channel [20–23]. The V-ATPases have been associated 
with cancer invasion, metastasis and drug resistance [19, 24–27]. Several pre-
clinical studies have reported the anticancer effects of V-ATPase inhibitors [28–32]. 
V-ATPase inhibitors will be beneficial for cancer patients given either in combina-
tion with cytotoxic agents or dual-acting (anticancer and V-ATPase inhibitor) 
agents. Thus, V-ATPases are emerging as an important target for the identification 
of potential novel chemotherapeutic agents. Despite the clear involvement of 
V-ATPases in cancer, to date, therapeutic use of V-ATPase targeting small mol-
ecules have not reached the clinic. Natural products macrolide antibiotics, such as 
bafilomycin and concanamycin, potently inhibit V-ATPases [33–37] (Figure 2), but 
their use is complicated by non-specific effects on other targets. Moreover, these 
molecules have been difficult to synthesize in large quantities. Despite huge efforts 
by both academic and pharmaceutical industry medicinal chemists, development 
of useful V-ATPase inhibitors has been limited because of the complicated chemical 
structures of existing natural inhibitors.
We have been actively involved in the design and development of novel small 
molecular agents for different types of cancers. Past few years, we have reported 
the chromene-, chromenopyridine-, and imidazoquinoline-based pharmaco-
phores as initial lead anticancer drug candidates through screening and drug 
development process [38–40]. Notably, we have identified the highly potent 
microtubule targeting anticancer agent (SP-6-27) for ovarian cancer [41]. Since 
then our laboratory has been active in identifying anticancer agents with differ-
ent mechanisms of action. In continuation of our drug discovery research, we 
recently initiated a collaborative effort on the V-ATPases as anti-cancer targets. 
Successful identification of new lead small molecule drugs for ovarian cancer by 
screening and drug development processes [41] inspired us to screen the library 
of compounds based on the literature of known V-ATPase inhibitors. We identi-
fied the bisbenzimidazole scaffold from screening process. Bisbenzimidazoles 
are nitrogen heterocycles with wide spectrum of biological activities. We 
Figure 2. 
Natural potent V-ATPase inhibitors.
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reported the focused set of bisbenzimidazoles as anticancer V-ATPase agents 
(Figure 3) [42]. Bisbenzimidazole derivatives (RP-3–RP-15) have been screened 
in selected human breast cancer (MDA-MB-231, MDA-MB-468, MCF-7) and 
ovarian cancer (cisplatin-sensitive A2780, cisplatin-resistant Cis-A2780 and 
PA-1) cell lines. Among this small set of bisbenzimidazoles, RP-15 demon-
strated high potency towards the epidermal growth factor receptor (EGFR) 
over expressed triple negative breast cancer (TNBC) cell line, MDA-MB-468 
(IC50 = 0.04 ± 0.02 μM). Very interestingly, RP-15 is not toxic to normal breast 
epithelial cells. It is nearly 40 times less toxic in the normal breast epithelial 
cell line, MCF10A (IC50 = 1.62 ± 0.14 μM). Furthermore, the bisbenzimidazole 
derivatives (Compound-25, RP-11 and RP-15) have demonstrated encouraging 
proton pump inhibition activity in MDA-MB-231. In particular our most effica-
cious anticancer analog RP-15 has shown comparable proton pump inhibition 
activity to standard agent Bafilomycin A1.
In the present study, we selected and screened top two bisbenzimidazole 
derivatives (RP-11 and RP-15) along with initial hit (compound 25) for proton 
pump inhibition activity in human hepatoma cells, Huh7.5 using pH indicator 
Lysosensor Yellow/Blue DND-160. These compounds have also been screened 
for their antiproliferative activity using BrDU incorporation assay in selected 
inflammatory breast cancer (IBC) cell lines (SUM149PT and SUM190PT) 
along with Huh7.5 human hepatoma cancer cell line. Additionally, RP-11 and 
Figure 3. 
Bisbenzimidazoles derivatives.
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RP-15 have been tested in NCI Developmental Therapeutics Program (DTP) 
nine major (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, 
melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) 60 
human cancer cell lines.
2. Methods
2.1 Chemical synthesis
We recently reported the synthesis and detailed characterization of all these 
new bisbenzimidazoles [42]. In brief, we developed a fast and efficient synthetic 
one pot procedure to prepare all these analogs (RP-3–RP-15). Condensation of 
4-(6-(4-methylpiperazin-1-yl)-1H, 30H-[2, 50-bibenzo [d]imidazol]-20-yl) phenol 
with substituted alkyl halides in the presence of cesium carbonate in dimethyl 
formamide (DMF). For the more detailed synthesis and spectral and analytical 
characterization of all these compounds please see Ref. [42].
2.2 Proton pump inhibition activity in human hepatoma (Huh7.5) cell line
We used Huh7.5 cell line for proton pump activity. Briefly, the Huh7.5 cells 
were cultured in DMEM media supplemented with 10% serum to a confluency of 
80%. The Huh7.5 cells were treated with the compounds (Compound-25, RP-11 
and RP-15) at a concentration of 12 μM for 20 minutes followed by incubation 
with Lysosensor Yellow/Blue DND-160 (10 μM) for 10 minutes at 37°C. The cells 
were visualized under the microscope.
2.3 Antiproliferative activity
Cell proliferation ELISA BrdU colorimetric (assay no. 11647229001; Roche, Basel, 
Switzerland) was used to quantify cell proliferation by the measurement of BrdU 
incorporated during DNA synthesis. Cells from a 90% confluent T-25 flask were 
seeded 100 μL/well of 96-well plates and incubated overnight. Dimethyl Sulfoxide 
(DMSO) stock solutions of the compounds (Compound-25, RP-11 and RP-15) 
were diluted in pure F-12 media and exposed to different concentrations for 24 and 
48 hours. Each concentration and controls were done in triplicates. The mean ± stan-
dard deviation (S.D.) was calculated and shown on the graph with untreated cells 
serving as a negative control, 20 minutes after adding the substrate, the absorbance 
was read at 370 nm. The compound concentration that inhibited cell growth by 
50% of the untreated control (IC50) was calculated from the dose response curves 
constructed by normalizing the data to percentages based of the negative control and 
a nonlinear regression analysis in GraphPad Prism Software 7 (GraphPad Software, 
San Diego, CA, USA). For the Huh7.5 cell line we used CellTiter-Glo Luminescent 
Cell Viability Assay kit (Promega, Madison, WI, USA).
2.4 The NCI 60 cell lines in vitro screening
The bisbenzimidazoles (RP-11 and RP-15) have been tested for growth inhibi-
tion against 60 human cancer cell lines from the NCI’s anticancer screening pro-
gram. The NCI’s screening procedure has been given in detail elsewhere [43–47] and 
presently DTP uses the sulforhodamine B (SRB) assay.
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3. Results and discussion
Inhibition of V-ATPase has shown the link between cell biophysical properties 
and proliferative signaling selectively in malignant hepatocellular carcinoma (HCC) 
cells, which provides a new strategy to combat HCC [48]. HCC is the third most 
common cause of cancer-related deaths worldwide. HCC is accounting for almost 
90% of primary malignant hepatic tumors in adults. In continuation of our work on 
V-ATPase inhibition, we used Huh7.5 cells for the proton pump inhibition activity. 
We have performed proton pump inhibitory activity of selected bisbenzimidazole 
derivatives (Compound-25, RP-11 and RP-15) in Huh7.5 cells using Lysosensor 
Yellow/Blue DND-160 protocol [49]. The DND-160 is a pH indicator and cellular 
compartments with acidic pH elicit yellow fluorescence when stained, while the 
destabilized compartments with higher pH elicit blue fluorescence.
The compound RP-15 displayed maximum inhibition of the proton-pump 
activity of V-ATPase followed by compound-25 and RP-11. The untreated cells 
showed the strong intensity of yellow fluorescence (converted to pseudo-green 
in the Figure 4A) while the cells treated with bisbenzimidazoles (Compound-25, 
RP-11 and RP-15) showed the strong intensity of blue fluorescence representing 
varying degree of destabilization of pH due to impaired vacuolar ATPase activity 
(Figure 4A and B). Additionally, these compounds have been tested for their cyto-
toxicity towards Huh7.5 cells using the CellTiter-Glo Luminescent Cell Viability 
Assay. The IC50 were calculated based on the results obtained for these compounds 
treated for 24 hours only for Huh7.5 cells compared to breast and ovarian cancer 
cell lines where we treated all test compounds for 48 hours. Bisbenzimidazoles, 
RP-11 and RP-15 have demonstrated very moderate antiproliferative activity 
towards Huh7.5 cells for 24 hours (Table 1).
High potency of bisbenzimidazole analog (RP-15) against the EGFR over 
expressed TNBC cell line (MDA-MB-468) inspired us to explore the selected bis-
benzimidazoles in other breast cancer cell lines for anticancer activity. We selected 
two IBC cell lines (triple negative SUM149PT and Het2 positive SUM190PT) for 
the in vitro screening process [50]. Both SUM149 and SUM190 cell lines have been 
established from primary IBC tumors. IBC is one of the highly invasive, metastatic 
and lethal variant of human breast cancer. Development of therapeutic targets and 
agents for IBC is still in very early stage and it represents an opportunity for medici-
nal chemists to develop novel (pre) clinical drug candidates.
In vitro screening of the bisbenzimidazoles (Compound-25, RP-11 and RP-15) 
towards these inflammatory cell lines has shown encouraging results (Figure 5  
and Table 1). Very interestingly our initial hit, compound-25 (SUM149PT: 
IC50 = 0.80 ± 0.08 μM; SUM190PT: IC50 = 0.43 ± 0.11 μM) and its structural analog 
RP-11 (SUM149PT: IC50 = 0.91 ± 0.15 μM; SUM190PT: IC50 = 0.49 ± 0.09 μM) 
have shown very good inhibition, whereas our TNBC lead RP-15 (SUM149PT: 
IC50 = 1.77 ± 0.08 μM; SUM190PT: IC50 = 2.08 ± 0.56 μM) has demonstrated 
moderate inhibition towards these IBC cell lines. The high potency shown by 
compound-25 and RP-11 towards IBC has given us more insights to develop new 
anticancer agents for it and we plan to explore the structure-activity relationship 
(SAR) studies based on the bisbenzimidazole scaffold in very near future.
The Development Therapeutic Program (DTP) of the National Cancer Institute’s 
60 human tumor cell lines screen was developed as an in vitro drug discovery tool. 
We submitted both compounds (RP-11 and RP-15) to the NCI Developmental 
Therapeutics Program (DTP) anticancer drug screen. Both of them have been first 
tested for three cell lines (MCF-7 breast cancer; NCI-H460 large-cell lung cancer; 
SF-268 glioma) to advance to the 60 cell line screen. This pre-screen process elimi-
nates the inactive compounds but preserves active agents for 60 cell line screening. 
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Both compounds have been advanced to 60 cell lines representing nine major cancers 
(leukemia, non-small cell lung, central nervous system, colon, melanoma, ovar-
ian, renal, prostate, and breast). Compounds have been tested over a broad range 
of concentrations against every cell line in the panel (five 10 fold dilutions starting 
Figure 4. 
(A) Staining of acidic compartments: Yellow signal (converted to pseudo-green) represents acidic pH, 
while the blue color represents slightly acidic to neutral pH. Huh7.5 cells were treated with the compounds 
(Compound-25, RP-11 and RP-15) at a concentration of 12 μM and standard Bafilomycin A1 at 
concentration of 2 μM for 20 minutes followed by incubation with Lysosensor Yellow/Blue DND-160 (10 μM) 
for 10 minutes at 37°C. The cells were visualized under the microscope. The DND-160 is a pH indicator 
and cellular compartments with acidic pH elicit yellow fluorescence when stained, while the destabilized 
compartments with higher pH elicit blue fluorescence. The expected yellow color showed yellowish green of the 
filters available in the microscope. (B) Fold change in overall acidification of Huh7.5 cells upon treatment with 
bisbenzimidazoles (Compound-25, RP-11 and RP-15) along with positive control BafilomycinA1.
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Figure 5. 
The cell viability (%) of breast cancer cell lines (SUM190PT and SUM149PT) following the exposure of 
various concentrations of bisbenzimidazoles (Compound-25, RP-11 and RP-15) for 48 hours.
Compd. IC50 ± SD (μM)
SUM149PT SUM190PT MDA-MB-468‡ MCF10A‡ Cis-A2780‡ Huh7.5†
C-25 0.80 ± 0.08 0.43 ± 0.11 0.72 ± 0.08 1.14 ± 0.13 3.95 ± 0.33 17.1 ± 0.85
RP-11 0.91 ± 0.15 0.49 ± 0.09 0.56 ± 0.05 1.55 ± 0.04 3.03 ± 0.18 17.0 ± 0.78
RP-15 1.77 ± 0.08 2.08 ± 0.56 0.04 ± 0.02 1.62 ± 0.14 1.34 ± 0.14 16.4 ± 0.65
Baf A1 ND ND ND 0.036 ± 0.04 0.008 ± 0.01 ND
ND: not determined.
‡Data from Ref. [42].
†The IC50 is calculated based on the results obtained from 24 hours drug treatment only.
Table 1. 
Half maximal inhibitory concentration of novel bisbenzimidazole analogs in different cancer cell lines.
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Figure 6. 
Dose response curves derived from screening of compound RP-11 (NSC: D-800436) in 60 cell line screen 
using nine major human cancer cell lines (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, 
melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer).
Figure 7. 
The mean graph representation of antitumor effects of compound RP-11 (NSC: D-800436).  The GI50 (50% 
of growth inhibition), TGI (total growth inhibition) and LC50 (50% of lethal concentration) mean graphs are 
derived from the dose response curves using Figure 6 from the initial screening.
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from 10−4 M concentration). Figures 6 and 8 describe the dose response curves for 
compounds RP-11 (NSC: D-800436) and RP-15 (NSC: D-800437) respectively. 
From these dose response curves three end points were calculated (GI50: 50% of 
growth inhibition; TGI: total growth inhibition; LC50: 50% of lethal concentration). 
Figures 7 and 9 demonstrate mean graph patterns for compound RP-11 and RP-15 
respectively. Mean graphs are created for GI50, TGI, and LC50 by plotting positive and 
negative values termed as deltas generated from dose response curves. More sensitive 
cell lines are displayed as bars that project to the right of the mean, whereas the less 
sensitive cell lines are displayed with bars projected to the left. The length of each bar 
is proportional to the relative sensitivity of the agent with the mean determination.
Both bisbenzimidazole analogs, RP-11 and RP-15 demonstrated very good 
cytotoxicity towards the majority of cancer cell lines in the 60 cell line panel. 
Compound RP-11 displayed growth inhibition and total growth inhibition to low 
micromolar range and is moderate towards LC50 for MCF7 (GI50: 0.32 μM, TGI: 
11.8 μM and LC50: 88.7 μM), MDA-MB-468 (GI50: 1.42 μM, TGI: 4.16 μM and LC50: 
28.2 μM) and MDA-MB-231 (GI50: 2.25 μM, TGI: 6.49 μM and LC50: 60.4 μM). 
Interestingly, it showed low micromolar range effects against other cell lines such as 
SR (GI50: 0.50 μM); NCI-H522 (GI50: 0.34 μM); COLO 205 (GI50: 0.37 μM); SF-268 
(GI50: 0.58 μM); OVCAR-3 (GI50: 0.62 μM) and MDA-MB-435 (GI50: 0.62 μM) 
(Table 2). Compound RP-15 shows similar behavior as RP-11. Compound RP-15 
exhibited GI50: 1.91 μM, TGI: 4.13 μM and LC50: 8.91 μM for the MDA-MB-468 
cell line, whereas a similar trend is observed for the MDA-MB-231 cell line (GI50: 
2.85 μM, TGI: 5.83 μM and LC50: 21.3 μM). Similarly, low micromolar growth inhibi-
tion was observed for other cell lines such as MDA-MB-435 (GI50: 1.97 μM), RXF 
Figure 8. 
Dose response curves derived from screening of compound RP-15 (NSC: D-800437) in 60 cell line screen 
using nine major human cancer cell lines (leukemia, non small cell lung cancer, colon cancer, CNS cancer, 
melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer).
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Figure 9. 
The mean graph representation of antitumor effects of compound RP-15 (NSC: D-800437).  The GI50 (50% of 
growth inhibition), TGI (total growth inhibition) and LC50 (50% of lethal concentration) mean graphs are 
derived from the dose response curves using Figure 8 from the initial screening.
Cell line RP-11 (μM) RP-15 (μM) Cell line RP-11 (μM) RP-15 (μM)
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50
Leukemia MDA- 
MB-435
0.62 2.14 5.66 1.97 3.99 8.10
CCRF-CEM 1.02 >100 >100 2.72 7.34 92.8 SK-MEL-2 1.64 3.59 7.89 19.7 3.5 75.0
HL-60(TB) 1.62 91.8 >100 4.71 29.1 100 SK-MEL-28 0.478 2.21 6.08 3.03 9.43 40.1
K-562 0.91 >100 >100 2.24 4.45 – SK-MEL-5 0.351 1.88 5.06 12.7 27.6 59.8
MOLT-4 2.81 >100 >100 3.12 10.7 100 UACC-257 1.71 5.92 35.9 20.5 38.3 71.4
RPMI-8226 4.11 35.5 >100 2.86 7.44 100 UACC-62 0.36 2.02 6.37 17.3 40.1 93.1
SR 0.50 21.9 >100 2.90 8.05 100 Ovarian cancer
Non-small cell Lung IGROV1 1.71 4.81 >100 7.69 31.6 100
A549/ATCC 8.05 35.2 >100 4.69 17.7 88.6 OVCAR-3 0.62 3.13 57.0 5.22 16.8 46.7
EKVX 6.56 46.3 >100 4.67 21.4 81.4 OVCAR-4 0.313 2.99 >100 10.1 25.5 64.0
HOP-62 1.56 14.5 >100 7.10 26.8 89.0 OVCAR-5 3.59 9.96 >100 2.96 9.96 33.8
HOP-92 2.16 9.71 >100 14.3 33.2 77.0 OVCAR-8 0.931 23.4 >100 4.69 18.6 81.5
NCI-H226 1.44 – >100 23.8 52.2 100 NCI/ 
ADR-RES
>100 >100 >100 35.7 >100 >100
NCI-H23 1.21 5.09 57.2 15.1 33.0 71.9 SK-OV-3 2.70 15.6 >100 18.0 36.0 72.0
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393 (GI50: 1.91 μM), HT29 (GI50: 1.78 μM), LOXIMVI (GI50: 1.84 μM), DU-145 (GI50: 
1.83 μM) and KM12 (GI50: 1.91 μM) (Table 2). Overall, the NCI 60 cell line results 
are encouraging for both new bisbenzimidazole derivatives.
4. Conclusions and future directions
In summary, our screening and drug discovery processes have identified the 
bisbenzimidazole (RP-15) as a potent anticancer V-ATPase inhibitor for TNBC 
and RP-11 as initial lead for the IBC. The compound RP-15 showed maximum 
inhibition of the proton-pump activity which is comparable to our standard agent 
Bafilomycin A1. The in vitro antiproliferative activity of these bisbenzimidazole 
analogs (Compound-25, RP-11 and RP-15) towards IBC cell lines revealed that 
compound-25 and its structural analog RP-11 could be possibly considered for fur-
ther exploration in other IBC cell lines. Bisbenzimidazoles RP-11 (NSC: D-800436) 
and RP-15 (NSC: D-800437) have demonstrated very good cytotoxicity towards 
the majority of cancer cell lines in the NCI 60 cell line panel. Overall, our research 
identified efficacious and selective anticancer V-ATPase inhibitors for TNBC and 
Cell line RP-11 (μM) RP-15 (μM) Cell line RP-11 (μM) RP-15 (μM)
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50
NCI-H322M 3.07 9.93 >100 11.6 23.8 48.8 Renal cancer
NCI-H460 3.63 14.7 >100 2.12 3.98 7.44 786.0 1.64 3.81 8.86 2.70 8.33 >100
NCI-H522 0.34 2.36 >100 13.6 38.1 >100 A498 1.21 3.39 9.54 17.5 35.1 70.3
Colon cancer ACHN 10.7 >100 >100 9.20 22.8 54.2
COLO 205 0.37 3.05 >100 12.9 30.0 69.8 CAKI-1 2.25 >100 >100 4.15 15.7 47.2
HCC-2998 1.78 3.78 8.03 5.06 18.5 56.7 RXF 393 1.80 3.63 7.32 1.91 3.84 –
HCT-116 0.36 2.46 >100 1.82 3.44 – SN12C 1.42 11.8 >100 4.00 15.4 66.2
HCT-15 38.7 >100 >100 12.1 28.1 65.4 TK-10 4.74 40.2 >100 18.2 38.8 83.0
HT29 0.58 >100 >100 1.78 4.07 9.30 UO-31 29.4 >100 >100 21.3 41.8 82.3
KM12 2.58 14.3 65.4 1.91 4.20 9.26 Prostate cancer
SW-620 0.90 10.2 36.5 2.12 3.96 7.37 PC-3 2.19 24.5 >100 2.63 5.81 21.8
CNS cancer DU-145 1.13 9.59 >100 1.83 3.40 6.29
SF-268 0.58 5.66 62.9 6.58 25.4 81.0 Breast cancer
SF-295 1.38 15.7 >100 2.34 6.22 48.4 MCF7 0.32 11.8 88.7 1.85 3.96 –
SF-539 1.22 2.83 6.59 11.5 26.1 59.5 MDA-MB- 
231/ATCC
2.25 6.49 60.4 2.85 5.83 21.3
SNB-19 1.87 10.5 52.9 2.15 4.09 7.79 HS578T 2.94 15.9 >100 10.5 37.1 >100
SNB-75 0.49 3.14 15.2 3.46 18.0 47.0 BT-549 1.76 3.96 8.91 17.5 40.1 91.7
U251 0.66 10.2 36.5 2.16 3.81 6.74 T-47D 1.00 9.09 >100 14.2 41.1 >100
Melanoma MDA- 
MB-468
1.42 4.16 28.2 1.91 4.13 8.91
LOX IMVI 0.85 2.83 8.66 1.84 3.67 –
MALME-3 M 0.16 1.55 4.61 12.2 27.2 60.4
M14 0.45 2.50 9.80 2.39 6.53 40.0
Table 2. 
The NCI 60 cancer cell line screening results.
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IBC. We will continue to explore the SAR with this exciting pharmacophore to 
identify the highly selective and potent V-ATPase inhibitors which will ultimately 
lead to the generation of investigational new drug (IND) candidates for the clinical 
testing in TNBC and IBC patients.
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